meta
|
evidence
COVID-19
Living systematic review and meta-analysis
***** adjuvant therapies
***** anti-inflammatoty and immuno-therapy
***** antiandrogenic
***** antiviral and associated therapy
***** control
***** Drugs for acid related disorders
miscellaneous
2-deoxy-D-glucose (2-DG)
acetylcysteine
alpha lipoic acid
anti-CK2
Aspirin
aviptadil
BLD-2660 (calpain inhibitor)
calcium channel blocker
camostat mesilate
Cannabidiol
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
dornase alfa
expectorants and mucolytics
honey
kinin-kallikrein inhibitors
melatonin
mouthrise and gargling agents
N-Acetylcysteine
nasal spray
natural killer (NK) cells
nicotin
nigella sativa oil
nitric oxide (gas Inhalation or releasing solution)
omega-3 Polyunsaturated Fatty Acids
ozonated autohemotherapy
plasma exchange
povidone-iodine
previfenon (EGCG)
prostacyclin
PUL-042 inhalation solution
pyridostigmine
radiotherapy
sabizabulin
sildenafil
triiodothyronine (T3)
***** Oral antidiabetic drugs
***** Renin-angiotensin-system-acting agents
***** vaccines
***** Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
death D28
deaths
deaths (time to event analysis only)
death or ventilation
hospital discharge
mechanical ventilation
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance